2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.

February 23 | 2022

2cureX releases the Interim report for the fourth quarter of 2021 on the 24th of February 2022 and on the 25th of February CEO Fernando Andreu, CSO Ole Thastrup and CFO Kenneth G. Johansen will present and discuss the report and provide a status of the European roll-out of 2cureX’s first two IndiTreat products in metastatic colorectal cancer.

Please join us on the Webinar on the 25th of February at 14:00 (CET).

Link for registration: https://www.2curex.com/2curex-webinar-q4-2021/

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first two IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se